S. Michael Imperiale

InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA.

Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA.

Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT.